search.noResults

search.searching

dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
Drug Discovery


References 1 Dimasi, JA, Feldman, L, Seckler,A,Wilson,A.Trends in risks associated with new drug development: Success rates for investigational drugs.Clin PharmacolTher. 2010 Mar;87(3):272-7. 2 DiMasi, JA,Grabowski,HG, Hansen, RW. Innovation in the pharmaceutical industry:New estimates of R&D costs. J Health Econ. 2016 May;47:20- 33. 3Wong,CH, Siah, KW, Lo,AW. Estimation of clinical trial success rates and related parameters. Biostatistics. 2019 Apr;20(2):273-86. 4Van den Haak,MA. Industry Success Rates 2004.CMR International; Surrey,UK: 2004. 2004. 5 Kinch,MS,Griesenauer, RH. 2017 in review: FDA approvals of new molecular entities. Drug DiscovToday. 2018;23(8):1469-73. 6Vasaikar, S, Bhatia, P, Bhati,a P, ChuYaiw, K.Complementary Approaches to ExistingTarget Based Drug Discovery for Identifying Novel DrugTargets. Biomedicines. 2016 Nov 21;4(4):27. 7 Jeffery,CJ.Multifunctional proteins: examples of gene sharing.Ann Med. 2003;35(1):28-35. 8 GNS,HS,GR, S,Murahari,M, Krishnamurthy,M.An update on Drug Repurposing: Re- written saga of the drug’s fate. Biomed Pharmacother. 2019 Feb;110:700-16. 9 Echeverri,CJ, Beachy, PA, Baum, B, Boutros,M, Buchholz, F,Chanda, SK et al.Minimizing the risk of reporting false positives in large-scale RNAi screens.Nat Methods. 2006 Oct;3(10):777-9.


therapeutic treatments for a more adapted medicine for patient benefits.


Dr Lieke Geerts is Senior Scientist at Charles River. She received her PhD degree in neuroscience from the VU University in Amsterdam and is currently a project leader at Charles River. Since joining the company she has gained experience in assay devel- opment, drug target validation and small molecule testing using a wide range of technologies and in various disease areas. A main focus has been the integration of CRISPR/Cas9 into the Charles River toolbox for supporting drug development pro- grammes.


Dr Laure Grand Moursel is Senior Scientist at Charles River. She received her PhD in neu- ropathology and cerebrovascular disorders from the Leiden University Medical Center. Before join- ing Charles River Laboratories she worked at Biomethodes on the directed evolution of proteins of therapeutic interest and at the Leiden University Medical Center where she specialised in the devel- opment of Heavy Chain antibodies. She currently works on drug target identification and validation using CRISPR/Cas9 gene editing technology in Charles River Early Discovery.


Dr Jeroen DeGroot is Senior Director at Charles River.He received his PhDinmedical biology from the University of Utrecht. Before being acquired by Charles River Laboratories, Dr DeGroot was the Director of Cell Biology at BioFocus and before that was a Research Manager at TNO for more than 13 years. At Charles River, he supports clients with innovative contract research services, from initial target identification, through hit identifica- tion, H2L&LOprogrammes, via in vivo pharma- cology and regulatory safety studies to IND.


Dr Ian Waddell is Executive Director, Biology at Charles River. He received his PhD in molecular medicine from the University of Dundee (UK) and secured a lectureship in Dundee before working at AstraZeneca,


followed by CRUK at the


Manchester Institute. Dr Waddell is the Executive Director of Biology in CRL, has a very strong interest in efficient drug discovery and is a lean six sigma black belt.


38


Drug DiscoveryWorld Summer 2019


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64